Sana Biotechnology, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| OPERATING ACTIVITIES: | ||||
| Net loss | $(90,444) | $(185,341) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
| Depreciation | 7,599 | 9,697 | ||
| Stock-based compensation expense | 16,329 | 19,127 | ||
| Change in the estimated fair value of contingent consideration | (28,361) | 6,173 | ||
| Change in the estimated fair value of success payment liabilities | (2,672) | 9,170 | ||
| Non-cash expense for operating lease right-of-use assets | 8,021 | 6,780 | ||
| Impairment of long-lived assets | - | 44,611 | ||
| Other non-cash items, net | (7,748) | (7,876) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other assets | 1,118 | 1,861 | ||
| Operating lease right-of-use assets and liabilities | (8,335) | (1,539) | ||
| Accounts payable | 154 | (3,356) | ||
| Accrued expenses and other liabilities | (4,582) | (10,494) | ||
| Net cash used in operating activities | (108,921) | (111,187) | ||
| INVESTING ACTIVITIES: | ||||
| Purchases of marketable securities | (123,374) | (51,209) | ||
| Proceeds from maturities of marketable securities | 110,025 | 26,761 | ||
| Purchases of property and equipment | (2,700) | (65) | ||
| Proceeds from disposal of assets | 316 | 771 | ||
| Net cash used in investing activities | (15,733) | (23,742) | ||
| FINANCING ACTIVITIES: | ||||
| Proceeds from employee stock purchase plan and exercise of stock options | 421 | 1,617 | ||
| Proceeds related to common stock financings, net | 89,622 | 109,724 | ||
| Proceeds from issuance of common stock allocated to stock purchase option | 3,688 | - | ||
| Principal payments, net for tenant improvement loan | (277) | (258) | ||
| Net cash provided by financing activities | 93,454 | 111,083 | ||
| Net decrease in cash, cash equivalents, and restricted cash | (31,200) | (23,846) | ||
| Cash, cash equivalents, and restricted cash at beginning of period | 76,065 | 131,398 | ||
| Cash, cash equivalents, and restricted cash at end of period | $44,865 | $107,552 | ||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||
| Operating lease right-of-use assets obtained in exchange for lease obligations | $2,056 | $ | - | |
| Cash received for tenant improvement allowances | $ | - | $891 | |
| Derecognition of operating lease right-of-use assets for lease modification | $(12,018) | $(2,724) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.